EU approves Acadia’s DAYBU for Rett syndrome symptoms in patients 5 and older - ACAD News | RalliesEU approves Acadia’s DAYBU for Rett syndrome symptoms in patients 5 and older
A
ACAD• European Commission approves DAYBU for Rett syndrome
- European Commission granted marketing authorization for Acadia’s DAYBU (trofinetide) in the EU for Rett syndrome neurobehavioral symptoms.
- Label covers adults and children aged 5 and older, positioning DAYBU as the first EU-approved treatment for Rett syndrome.
- Authorization backed mainly by Phase 3 LAVENDER results, citing significant gains on RSBQ and CGI-I endpoints.
•
